Dr. Gallinson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
95 Madison Ave
Morristown, NJ 07960Phone+1 973-538-5210Fax+1 973-644-9657
Education & Training
- New York Medical College at St Vincent's Hospital and Medical Center of New YorkFellowship, Hematology and Medical Oncology, 2001 - 2004
- Atlantic Health System/Overlook Medical CenterResidency, Internal Medicine, 1998 - 2001
- Rowan University School of Osteopathic MedicineClass of 1998
Certifications & Licensure
- FL State License 2022 - Present
- NJ State License 2004 - 2025
- PA State License 2012 - 2021
- NY State License 2001 - 2004
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Publications & Presentations
PubMed
- Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.Michael Wang, Tadeusz Robak, Kami J Maddocks, Tycel Phillips, Stephen D Smith
Blood Advances. 2024-09-10 - Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial.Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens
Haematologica. 2024-09-05 - 831 citationsPemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 studyGhassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi
The Lancet. Oncology. 2020-05-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: